The Pediatric Oncology Group (POG) is composed of 37 institutions and 21 affiliate institutions who have pooled their patient resources and scientific expertise to study the natural history of childhood cancer, to develop effective therapeutic regimens and to develop clinical trials of new therapeutic agents in children with cancer. There are 637 member investigators which includes pediatric oncologists, pathologists, surgeons, radiation therapists, radiologists, epidemiologists, neurologists, cytogeneticists, immunologists, pharmacologists, psychiatrists and statisticians. Reference laboratories for immunology, steroid receptors, cytogenetics, bone marrow culture, HLA typing, immunophenotyping, pharmacology studies and catacholamine levels are established at various member institutions to further investigate the natural history of childhood cancer and to investigate factors which may be of importance in prognosis. The Group Chairman provides executive and scientific guidance and is responsible for creating an environment which will encourage the development of research protocols of the highest scientific merit. The specific objective of the POG Operations Office is to provide the facilities and staff that serve as the central office for collection, processing, classification and distribution of essential and vital data and information that is necessary for member investigators to participate in the research activities of the Group. This office will prepare, edit, process and distribute POG protocols from the initial concept to activation and will monitor the progress of studies during their active phase as well as preparation of manuscripts for publication. It will be responsible for arranging, conducting and supervising POG meetings and generating and distribution minutes of these meetings. This office will arrange and coordinate quality control institutional audits. All of the activity of the Operations Office will be coordinated with that of the Statistical Office. This application is requesting continued funding for the POG Operations Office and includes budgets for standing committees and reference laboratories.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA030969-08
Application #
3557143
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1990-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
8
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Washington University
Department
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Tower, Richard L; Jones, Tamekia L; Camitta, Bruce M et al. (2014) Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 36:353-61
Mansour, Marc R; Abraham, Brian J; Anders, Lars et al. (2014) Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346:1373-7
Duffner, Patricia K; Armstrong, Floyd Daniel; Chen, Lu et al. (2014) Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A rep J Pediatr Hematol Oncol 36:8-15
Lupo, Philip J; Zhou, Renke; Skapek, Stephen X et al. (2014) Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Int J Cancer 134:431-6
Lupo, Philip J; Danysh, Heather E; Skapek, Stephen X et al. (2014) Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Cancer Causes Control 25:905-13
Kelly, Katherine P; Hooke, Mary C; Ruccione, Kathleen et al. (2014) Children's Oncology Group nursing research framework. Semin Oncol Nurs 30:17-25
Kreissman, Susan G; Seeger, Robert C; Matthay, Katherine K et al. (2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14:999-1008
Kelly, Michael E; Lu, Xiaomin; Devidas, Meenakshi et al. (2013) Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9). J Pediatr Hematol Oncol 35:509-13
Salzer, Wanda L; Jones, Tamekia L; Devidas, Meenakshi et al. (2012) Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatr Blood Cancer 59:834-9
Schrappe, Martin; Hunger, Stephen P; Pui, Ching-Hon et al. (2012) Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366:1371-81

Showing the most recent 10 out of 198 publications